Aldosterone receptor antagonism in heart failure

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1126-1133

  Jennings, Douglas L ^a   Kalus, James S ^a,b   O'Dell, Kate M ^c,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d DAVID GRANT MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Antagonism; Heart failure; Left ventricular dysfunction; RAAS; Renin angiotensin aldosterone system

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE;

CLINICAL TRIAL; COLLAGEN SYNTHESIS; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; MASTALGIA; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEXUAL DYSFUNCTION; SHORT SURVEY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ALDOSTERONE;

EID: 23244448928     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1126     Document Type: Short Survey

References (33)

1. Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002;144:S8-11.
2. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
3. G.D. Searle LLC, subsidiary of Pharmacia Corporation. Aldactone (spironolactone tablets, USP) prescribing information. Chicago; July 2003.
4. G.D. Searle LLC, subsidiary of Pfizer. Inspra (eplerenone) tablets prescribing information. New York; 2004.
5. Johnson JA, Parker RB, Patterson JH. Heart failure. In: DiPiro JT, Talbert RL, Yee GC, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York: McGraw-Hill, 2002:185-218.
6. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (commiuee to revise the 1995 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2001;38:2101-13.
7. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: the RESOLVD pilot study. Circulation 1999;100:1056-64.
8. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS trial study group. Circulation 1990;82:1730-6.
9. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohormonal activation in the survival and ventricular enlargement (SAVE) study. Eur Heart J 1998;19:1552-63.
10. Stier CT, Koenig S, Lee DY, et al. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis 2003;5:102-18.
11. Lombes M, Alfaidy N, Eugene E, et al. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.
12. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001;94:378-83.
13. Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-72.
14. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001;28:1002-6.
15. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
16. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 2000;102:2700-6.
17. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.
18. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines of the management of patients with ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines of the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671-719.
19. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
20. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
21. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-8.
22. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
23. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B. Effects of spironolacione on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 2000;86:649-53.
24. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolacione to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
25. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
26. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
27. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
28. Flack JM, Oparil S, Pratt H, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
29. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oikman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92:38-42.
30. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.
31. Burgess ED, Lacourciere Y, Ruilope-Uriloste LM, et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003;25:2388-404.
32. Anonymous. Eplerenone on cardiac remodeling in patients with left ventricular systolic dysfunction and mild to moderate heart failure. Available from www.clinicaltrials.gov/ct/show/NCT00082589?order=1. Accessed February 4, 2005.
33. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.